December 2025
1. THIERENS N, Verdonk RC, Lohr JM, van Santvoort HC, et al
   Chronic pancreatitis.
   Lancet. 2025;404:2605-2618.
   

   >> Share

   
   November 2025
2. BREDIN P, Koerkamp BG, O'Kane GM
   Neoadjuvant quadruplet chemotherapy PAXG for pancreatic cancer.
   Lancet. 2025 Nov 20:S0140-6736(25)01864-1. doi: 10.1016/S0140-6736(25)01864.
   

   >> Share

   
   
3. RENI M, Macchini M, Orsi G, Procaccio L, et al
   Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 x 2 factorial phase 3 trial.
   Lancet. 2025 Nov 20:S0140-6736(25)01685-X. doi: 10.1016/S0140-6736(25)01685.
   

   >> Share

   
   April 2025
4. STOOP TF, Javed AA, Oba A, Koerkamp BG, et al
   Pancreatic cancer.
   Lancet. 2025;405:1182-1202.
   

   >> Share

   
   April 2024
5. MAITRA A, Topol EJ
   Early detection of pancreatic cancer and AI risk partitioning.
   Lancet. 2024;403:1438.
   

   >> Share

   
   January 2024
6. KAIMAKLIOTIS PI, Kochman ML
   Prophylactic pancreatic stent placement to prevent pancreatitis after ERCP.
   Lancet. 2024 Jan 11:S0140-6736(23)02719-8. doi: 10.1016/S0140-6736(23)02719.
   

   >> Share

   
   
7. ELMUNZER BJ, Foster LD, Serrano J, Cote GA, et al
   Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial.
   Lancet. 2024 Jan 11:S0140-6736(23)02356-5. doi: 10.1016/S0140-6736(23)02356.
   

   >> Share

   
   December 2023
8. WANG S, Wang Y, Zhang Z, Lu W, et al
   Acute pancreatitis as a key to diagnosis of hyperhomocysteinemia in a 12-year-old boy caused by CBS gene mutation.
   Lancet. 2023;402:2235-2236.
   

   >> Share

   
   September 2023
9. BESSELINK MG, Wilmink JW
   Treating metastatic pancreatic ductal adenocarcinoma: NALIRIFOX as new standard?
   Lancet. 2023 Sep 11:S0140-6736(23)01521-0. doi: 10.1016/S0140-6736(23)01521.
   

   >> Share

   
   
10. WAINBERG ZA, Melisi D, Macarulla T, Pazo Cid R, et al
    NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
    Lancet. 2023 Sep 11:S0140-6736(23)01366-1. doi: 10.1016/S0140-6736(23)01366.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share